The Centers for Disease Control and Prevention (CDC) issued new warnings that kratom use is driving an increase in poison-control calls [1, 2].

This development signals a growing effort by health officials to scrutinize the supplement. Because kratom possesses opioid-like effects, regulators are concerned about the rising number of reported poisonings among users [1, 2].

Kratom is sold legally across most of the U.S. [1, 2]. However, the legal landscape is shifting as some jurisdictions move toward prohibition. In Kentucky, the state has enacted a ban on the supplement, a move that a supplement company is currently challenging in court [3].

While the CDC warns of a general rise in poison-control calls linked to the substance [1, 2], some health warnings focus specifically on 7-hydroxymitragynine [4]. This compound is a potent opioid by-product found in kratom extracts [4].

The increase in medical emergencies has prompted lawmakers and health agencies to re-examine the safety profile of the supplement. Officials are particularly concerned with the lack of standardization in kratom products sold to the public [1, 2].

As the CDC continues to monitor these trends, the tension between consumer access and public health safety remains a central point of contention for regulators [1, 2].

“The CDC has issued new warnings that kratom use is driving an increase in poison-control calls.”

The CDC's warnings indicate a shift toward stricter oversight of the kratom market. By linking the supplement to an increase in poison-control center data, health officials are building a clinical case that may be used to support more widespread bans or federal regulation, similar to the legal challenges currently unfolding in Kentucky.